Publications by authors named "O E Akilov"
Purpose: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL).
Patients And Methods: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles.
The odyssey of diagnosis of mycosis fungoides: Sailing beyond clonality and histology.
J Eur Acad Dermatol Venereol
October 2024
Article Synopsis
- Sézary syndrome (SS) is a rare type of skin lymphoma, and this study analyzed treatment trends for SS patients in the USA between 2018 and 2020.* -
- A retrospective analysis of patient claims data revealed that while some systemic treatments decreased in usage, mogamulizumab became the most common therapy by 2020, with variations seen across different states.* -
- The findings emphasize the need for more research to understand what influences treatment choices for SS, especially given the geographical differences in therapy utilization.*
Article Synopsis
- There are currently no established maintenance protocols for cutaneous lymphomas, prompting a study to analyze treatments and outcomes during the COVID-19 pandemic.
- The research included data from 149 patients across nine international institutions, revealing younger patients tended to have earlier stages of the disease and more commonly received skin-directed therapies.
- Findings indicated that treatment interruptions were linked to disease progression and poorer outcomes, with patients experiencing interruptions twice as likely to progress compared to those who maintained their treatments, highlighting the importance of continuous maintenance therapies.
Sézary syndrome (SS) is an aggressive leukemic expansion of skin-derived malignant CD4+ T cells. Drug monotherapy often results in disease relapse because of the heterogenous nature of malignant CD4+ T cells, but how therapies can be optimally combined remains unclear because of limitations in understanding the disease pathogenesis. We identified immunologic transitions that interlink mycosis fungoides with SS using single-cell transcriptome analysis in parallel with high-throughput T-cell receptor sequencing.
View Article and Find Full Text PDF